VC-backed Concert Pharmaceuticals files for IPO – Fortune


Fortune reported that Concert Pharmaceuticals has filed for a $74.75 million IPO. The company plans on listing the stock on the NASDAQ under the ticker symbol “CNCE.” UBS and Wells Fargo are the lead underwriters. Based in Lexington, Mass., Concert Pharmaceuticals produces drugs that treat spasticity and kidney disease. Its backers nclude Three Arch Partners, TVM Capital, GlaxoSmithKline, Brookside Capital, Skyline Ventures, Fidelity Investments, Greylock Partners and Flagship Ventures.

Take your pick!

  • Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
  • VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now

Sign up to our Newsletter

Receive updates from our PE HUB Wire and Top Stories of the Week newsletters:

We will not send you spam, and we don't share your email address with 3rd parties.